Form 4 Filing for Aquestive Therapeutics, Inc. - Insider Transaction

Thomas A. Zalewski, Chief Legal Officer of Aquestive Therapeutics, Inc., reported a transaction on May 18, 2026. He acquired 100,000 shares of Common Stock, represented by restricted stock vesting over three years, with an initial price of $0.0. Additionally, he was granted 75,000 non-qualified stock options to purchase Common Stock, also vesting over three years, with an exercise price of $4.135 per share. These options expire on May 8, 2036. The transactions were reported on a Form 4 filing.